Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo may reduce chronic transplant complications in blood cancer patients

NCT ID NCT03680092

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 31 times

Summary

This study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the risk of chronic graft-versus-host disease (GVHD) after a stem cell transplant in people with high-risk blood cancers. GVHD happens when donor cells attack the patient's body. The trial enrolled 43 participants and compared the new drug combo to standard care. The main goal was to see if fewer patients developed moderate or severe chronic GVHD one year after transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • UC San Diego Moores Cancer Center

    La Jolla, California, 92093, United States

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive graft versus host disease hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Hodgkins lymphoma myelodysplastic syndrome myeloproliferative neoplasm neoplasm non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.